ArticleProceedings of the National Academy of Sciences of the United States of America2025
Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Toward Precision Bioconjugation: Chemical Strategies for Site-Selective Cysteine Conjugation.Precision chemistry · 2026Review
- Disruption of the AgMOBP1-PfSyn5 interface abolishes malaria transmission.bioRxiv : the preprint server for biology · 2026Article
- Engineering a Membrane-Anchored CreER Recombinase With Reduced Basal Activity for In Vitro Recombination.Biotechnology journal · 2026Article
- Advances in Mass Spectrometry Instrumentation and Methodology for Analysis of Alternative Protein Isoforms.Journal of mass spectrometry : JMS · 2026Review
- Review
- RAS-membrane interaction and oligomerization: there is more than meets the eye.Biochemical Society transactions · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Anna E MaciagNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0003-2641-4212
Yue YangLawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biotechnology and Biosciences Division, Livermore, CA 94550.
Alok K SharmaNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0002-1329-3944
David M TurnerNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Caroline J DeHartNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Hazem AbdelkarimDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607.
Lixin FanBasic Science Program, Frederick National Laboratory for Cancer Research, Small-Angle X-ray Scattering Facility of the National Cancer Institute, Frederick, MD 21702.
Brian P SmithNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Vandana KumariNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Marcin DybaNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Megan RigbyNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Jean A Castillo BadilloNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Lauren AdamsDepartment of Molecular Biosciences, Northwestern University, Evanston, IL 60208.
Luca FornelliDepartment of Chemistry, Proteomics Center of Excellence, Northwestern University, Evanston, IL 60208.ORCID 0000-0001-6334-1046
Stephen FoxNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Alla BrafmanNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Thomas TurbyvilleNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
William GilletteNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0002-8592-3642
Simon MessingNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0001-8991-2097
Constance AgamasuNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Andrew L WolfeDepartment of Cellular and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158.
Stephan GysinDepartment of Cellular and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158.
Albert H ChanNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0001-5809-8483
Dhirendra K SimanshuNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0002-9717-4618
Dominic EspositoNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0002-9987-1687
Oleg ChertovNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0002-0426-2521
Andrew G StephenNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0002-8259-621X
Michelle ArkinDepartment of Pharmaceutical Chemistry, Small Molecule Discovery Center, University of California, San Francisco, CA 94143.ORCID 0000-0002-9366-6770
Adam RensloDepartment of Pharmaceutical Chemistry, Small Molecule Discovery Center, University of California, San Francisco, CA 94143.ORCID 0000-0002-1240-2846
Neil L KelleherDepartments of Chemical and Biological Engineering, Chemistry, and Molecular Biosciences, the Chemistry of Life Processes Institute, and the Proteomics Center of Excellence, Northwestern University, Evanston, IL 60208.ORCID 0000-0002-8815-3372
Vadim GaponenkoDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607.
Felice C LightstoneLawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biotechnology and Biosciences Division, Livermore, CA 94550.
Dwight V NissleyNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0001-7523-116X
Frank McCormickNational Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.ORCID 0000-0002-6619-7120
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MResearch Center in Minority Institutions (RCMI) at City CollegeU54MD017979 · NIMHD · CITY COLLEGE OF NEW YORK · PI M. Felice Marina GHILARDI · 2024 to 2026
$15.9MTR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6MCellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRASR00CA226363 · NCI · HUNTER COLLEGE · PI WOLFE, ANDREW L · 2021 to 2023
$747kCellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRASK99CA226363 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOLFE, ANDREW L · 2018 to 2020
$399kNCI NIH HHS 75N91019D00024NCI NIH HHS K99 CA226363NCI NIH HHS R00 CA226363NIGMS NIH HHS P41 GM108569NIMHD NIH HHS U54 MD017979
Abstract
PubMed holds no abstract for this paper.
Indexed as
CysteineProtein Processing, Post-TranslationalProto-Oncogene Proteins p21(ras)AnimalsCell ProliferationHumansMiceProtein PrenylationCysteineKRAS protein, humanProto-Oncogene Proteins p21(ras)C185covalent inhibitorHVRKRASKRAS4b
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.